Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

Passaro, Antonio; Pochesci, Alessia; Spitaleri, Gianluca; Catania, Chiara; Noberasco, Cristina; Del Signore, Ester; de Marinis, Filippo

Passaro, Antonio; Pochesci, Alessia; Spitaleri, Gianluca; Catania, Chiara; Noberasco, Cristina; Del Signore, Ester; de Marinis, Filippo.

Afiliação

Passaro A; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
Pochesci A; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
Spitaleri G; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
Catania C; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
Noberasco C; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
Del Signore E; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
de Marinis F; Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.

J Thorac Dis ; 8(3): E217-20, 2016 Mar.

Article em En | MEDLINE | ID: mdl-27076973

Palavras-chave

LUX-Lung 7 (LL7); Non-small cell lung cancer (NSCLC); afatinib; common mutations; epidermal growth factor receptor (EGFR)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2016 Tipo de documento: Article